Cannabinoid receptors and their relationships with neuropsychiatric disorders.
F Gambi, D De Berardis, G Sepede, R Quartesan, E Calcagni, R M Salerno, C M Conti, F M Ferro
International journal of immunopathology and pharmacology 2005 DOI: 10.1177/039463200501800103 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | The authors propose that endocannabinoids form a new class of neuromodulators made on demand rather than stored in vesicles, and that the endogenous cannabinoid system may be centrally involved in neuropsychiatric disorders, pain, spasticity, and neuroprotection. They suggest a third receptor, CB3, awaits cloning, and discuss a possible role in schizophrenia. |
Abstract
Cannabinoids are the constituents of the marijuana plants. The central effects of exogenous cannabinoids are implicated in enhancing mood, altering emotional states, and interfering in the formation of short-term memory. Cannabinoid receptors are G protein-coupled receptors with seven transmembrane domains that are expressed on the cell surface with their binding domain exposed to the extracellular space. To date, two cannabinoid receptors have been cloned, CB1 and CB2. Recent evidence suggests that a third CB3 receptor is out there, waiting to be cloned. The endocannabinoids may represent the first members of a new classes of neuromodulators, that are not stored in cell vesicles, but rather synthesised by the cell on demand. The endogenous cannabinoid system could play a central role in several neuropsychiatric disorders and is also involved in other conditions such as pain, spasticity and neuroprotection. Implication of cannabinoid system in the pathogenesis and development of schizophrenia is also discussed.